Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote in favor of the pasta that makes good dieting pleasant! - 2Famous Versatile Brands: Your Decision
- 3U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- 4Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- 5Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip
- Find Serenity: 10 Stunning Setting up camp Areas
- Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- Heart disease risk greater for women with a common condition they may not be aware they have
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- Investigating Inside Plan and Home Style: Change Your Residing Space
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- 'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- Nations for Rock Climbing
